Syndax Pharmaceuticals, Inc. (SNDX)

20.79 -0.18 (-0.86%) 收市：04:00PM EDT

Syndax Pharmaceuticals, Inc.

35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400
https://www.syndax.com

版塊: Healthcare
行業: Biotechnology
全職員工: 184

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Michael A. Metzger M.B.A.	CEO & Director	1.1M	126.68k	1971
Dr. Neil Gallagher M.D., Ph.D.	President, Head of Research & Development	720.46k	無	1964
Mr. Keith Alan Goldan CPA	CFO, Treasurer & Chief Accounting Officer	674.65k	無	1971
Mr. Luke J. Albrecht	Senior VP, General Counsel & Secretary	631.36k	387.36k	1979
Dr. Catherine Madigan M.D.	Chief Medical Officer	655.84k	無	1972
Dr. Peter Ordentlich B.Sc., Ph.D.	Co-Founder & Chief Scientific Officer	無	無	1969
Dr. Richard A. Heyman Ph.D.	Co-Founder	無	無	1957
Dr. Ronald M. Evans Ph.D.	Co-Founder, Advisor and Chair of Scientific Advisory Board	無	無	1949
Dr. Michael Downes Ph.D.	Co-Founder	無	無	無
Sharon Klahre	Vice President of Investor Relations & Communications	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

公司管治

截至 2024年4月1日 止，Syndax Pharmaceuticals, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：8；董事會：8；股東權利：8；現金賠償：7。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。